The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

Dmitrij A. Sychev; Ghulam Md Ashraf; Andrey A. Svistunov; Maksim L. Maksimov; Vadim V. Tarasov; Vladimir N. Chubarev; Vitalij A. Otdelenov; Natal’Ja P. Denisenko; George E. Barreto; Gjumrakch Aliev

doi:10.2147/DDDT.S149069

The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

Dmitrij A. Sychev
, Ghulam Md Ashraf
, Andrey A. Svistunov
, Maksim L. Maksimov
, Vadim V. Tarasov
, Vladimir N. Chubarev
, Vitalij A. Otdelenov
, Natal’Ja P. Denisenko
, George E. Barreto
, Gjumrakch Aliev

Russian Medical Academy of Postgraduate Education
King Fahd Medical Research Center
Sechenov First Moscow State Medical University
Kazan State Medical Academy
Universidad Javeriana
Universidad Autónoma de Chile
GALLY International Biomedical Research Consulting LLC
University of Atlanta
Russian Academy of Sciences

Research output: Contribution to journal › Review article › peer-review

Abstract

Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays.

Original language	English
Pages (from-to)	1147-1156
Number of pages	10
Journal	Drug Design, Development and Therapy
Volume	12
DOIs	https://doi.org/10.2147/DDDT.S149069
Publication status	Published - 8 May 2018
Externally published	Yes

Keywords

Cytochrome CYP450
Drug interaction
Drug metabolism
Phenotyping

Access to Document

10.2147/DDDT.S149069

Cite this

Sychev, D. A., Ashraf, G. M., Svistunov, A. A., Maksimov, M. L., Tarasov, V. V., Chubarev, V. N., Otdelenov, V. A., Denisenko, NJ. P., Barreto, G. E., & Aliev, G. (2018). The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy, 12, 1147-1156. https://doi.org/10.2147/DDDT.S149069

@article{98e3caa7687a489ca0eb1760f3ed5873,

title = "The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo",

abstract = "Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays.",

keywords = "Cytochrome CYP450, Drug interaction, Drug metabolism, Phenotyping",

author = "Sychev, \{Dmitrij A.\} and Ashraf, \{Ghulam Md\} and Svistunov, \{Andrey A.\} and Maksimov, \{Maksim L.\} and Tarasov, \{Vadim V.\} and Chubarev, \{Vladimir N.\} and Otdelenov, \{Vitalij A.\} and Denisenko, \{Natal{\textquoteright}Ja P.\} and Barreto, \{George E.\} and Gjumrakch Aliev",

note = "Publisher Copyright: {\textcopyright} 2018 Sychev et al.",

year = "2018",

month = may,

day = "8",

doi = "10.2147/DDDT.S149069",

language = "English",

volume = "12",

pages = "1147--1156",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

}

TY - JOUR

T1 - The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

AU - Sychev, Dmitrij A.

AU - Ashraf, Ghulam Md

AU - Svistunov, Andrey A.

AU - Maksimov, Maksim L.

AU - Tarasov, Vadim V.

AU - Chubarev, Vladimir N.

AU - Otdelenov, Vitalij A.

AU - Denisenko, Natal’Ja P.

AU - Barreto, George E.

AU - Aliev, Gjumrakch

PY - 2018/5/8

Y1 - 2018/5/8

N2 - Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays.

AB - Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays.

KW - Cytochrome CYP450

KW - Drug interaction

KW - Drug metabolism

KW - Phenotyping

UR - https://www.scopus.com/pages/publications/85046669972

U2 - 10.2147/DDDT.S149069

DO - 10.2147/DDDT.S149069

M3 - Review article

C2 - 29780235

AN - SCOPUS:85046669972

SN - 1177-8881

VL - 12

SP - 1147

EP - 1156

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

ER -

The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this